← All trials
NCT05794230
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2023
- Primary completion
- Sep 8, 2025
- Completion date
- Sep 8, 2025
- First posted
- Apr 3, 2023
- Last posted
- Dec 5, 2023
- Enrollment
- 1528
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- Measles, Mumps and Rubella Vaccine, Live
- typhoid vi polysaccharide vaccine
- hepatitis a vaccine, inactivated
- attenuated measles vaccine - Edmonston strain
- live attenuated varicella vaccine
- bivalent opv
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- inactivated varicella vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- tetanus toxoid
- human rotavirus, live attenuated
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.